کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3305108 | 1210349 | 2012 | 9 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms? Do antiplatelets increase the risk of bleeding after endoscopic submucosal dissection of gastric neoplasms?](/preview/png/3305108.png)
BackgroundIt is rarely known whether antiplatelets increase the risk of bleeding after endoscopic submucosal dissection (ESD).ObjectiveTo evaluate the effect of antiplatelets on post-ESD bleeding.DesignRetrospective study.SettingSingle, tertiary-care referral center.PatientsThis study involved 1591 gastric neoplasms (815 adenomas and 776 early gastric cancers) in 1503 patients who had ESD between April 2005 and April 2010.InterventionESD.Main Outcome MeasurementsOvert hematemesis/hematochezia, a drop of hemoglobin >2 g/dL from baseline, or requirement of endoscopic hemostasis, angiographic embolization, and/or transfusion.ResultsOf 1591 subjects, 274 took antiplatelets, among whom 102 discontinued them for 7 days or more before ESD. Post-ESD bleeding occurred in 94 subjects including 20 from the continuation group, 6 from the withdrawal group, and 68 from the no-antiplatelet group. In univariate analysis, antiplatelets, early gastric cancer (EGC), comorbidity, and specimen diameter were related to post-ESD bleeding. In multivariate analysis, EGC (odds ratio [OR] 1.839; 95% confidence interval [CI], 1.168-2.896; P = .009), comorbidity (OR 2.246; 95% CI, 1.280-3.939; P = .005), and specimen diameter (OR 2.315; 95% CI, 1.282-4.180; P = .005) were independent risk factors of post-ESD bleeding, whereas antiplatelet usage was not (OR 1.596; 95% CI, 0.877-2.903; P = .126). In subgroup analysis, continuous antiplatelet usage was not found to be an independent risk factor of post-ESD bleeding in multivariate analysis (OR 2.027; P = .146). Among 102 subjects who discontinued antiplatelets, 1 developed an acute cerebral infarction (1.0%).LimitationA retrospective, single-center analysis.ConclusionIn ESD for antiplatelet users, continuous administration was not found to have an independent significant association with bleeding.
Journal: Gastrointestinal Endoscopy - Volume 75, Issue 4, April 2012, Pages 719–727